查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1320222

基因重组促血红细胞生长素市场:各类型，各适应症，各最终用途，各国，各地区-2023-2030年的产业分析，市场规模，市场占有率，预测

Recombinant Erythropoietin Market with COVID-19 Impact Analysis, By Type, By Indication, By End-Use, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 250 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2022年重组促红血球生成素市场规模将达6,85128万美元，2023年至2030年复合年增长率为2.1%

重组促红血球生成素市场 - 市场动态：

慢性肾臟病 (CKD) 发生率的增加和对有效贫血治疗的需求推动了市场需求

慢性肾病 (CKD) 发病率的增加以及对有效贫血治疗的需求正在推动对重组促红血球生成素 (rEPO) 的需求。rEPO，也称为阿法促红血球生成素，用于增加红血球形成，缓解贫血症状，并最大限度地减少输血需求。由于老化和生活方式的改变，全球 CKD 盛行率不断增加，医疗保健部门对 rEPO 作为治疗 CKD 患者贫血的基本治疗选择的需求不断增加。

重组促红血球生成素市场 – 主要见解：

  • 根据研究分析师的分析，全球重组促红血球生成素市场预计在预测期内（2023-2030 年）每年将以约 2.1% 的复合年增长率成长。
  • 由于慢性肾病 (CKD) 发病率的增加以及对有效贫血治疗的需求，重组促红血球生成素产业预计将以显着的速度增长。
  • 按类型区隔，预计 Epoetin Alfa 将在 2022 年占最大的市场占有率。
  • 从迹象来看，癌症相关贫血是 2022 年的主要类型。
  • 按地区划分，亚太地区将在 2022 年实现销售额领先

重组红血球生成素市场 - 区隔分析：

全球重组促红血球生成素市场根据类型、适应症、最终用途和地区进行区隔。

市场依类型分为两类：阿法依泊汀（epoetin alfa）、阿法达贝泊汀（darbepoetin alfa）。促红血球生成素 α 是一种重组促红血球生成素 (rEPO)，需求量很大，因为它经常用于治疗慢性肾臟病、癌症化疗和其他疾病引起的贫血。阿尔法依泊汀促进红血球的合成，有助于减轻贫血症状并提高患者的生活品质。

市场依适应症分为四类：慢性肾臟病相关贫血（CKD）、癌症相关贫血、HIV相关贫血等。与癌症相关的贫血区隔市场占主导地位，预计在预测期内将保持其主导地位。重组促红血球生成素（rEPO）对于治疗癌症相关贫血有高的需求。rEPO，特别是 Epoetin Alfa，用于增加红血球合成，减少输血需求并改善癌症患者的整体健康。

重组促红血球生成素市场 - 地理洞察：

从地理来看，市场遍布北美、拉丁美洲、欧洲、亚太地区和中东非洲。这些地区根据其开展业务的国家进一步划分。亚太地区对重组促红血球生成素 (rEPO) 的需求量很大有几个原因。该地区的许多患者患有与贫血相关的疾病，例如慢性肾臟病和癌症。此外，该地区人口迅速老化和慢性病发病率的增加增加了对 rEPO 作为贫血管理治疗选择的需求。此外，医疗保健基础设施的改善和医疗技术的进步促使亚太市场 rEPO 的使用量增加。因此，製药公司正在增加在该地区的业务，以满足对 rEPO 和其他生物製剂不断增长的需求。

重组红血球生成素市场 - 竞争格局：

重组促红血球生成素（rEPO）在贫血相关疾病的治疗中发挥重要作用，面临激烈的竞争。多家製药公司参与了rEPO的开发和行销，创造了竞争环境。该市场由拥有知名品牌和已开发分销网络的主要参与者主导。公司透过专注于产品功效、安全性和成本效益来寻求确保竞争优势。此外，正在进行的研究和开发工作正在改进配方和给药方法，以提高患者的舒适度和依从性。严格的监管合规和专利保护进一步影响竞争者的力量。

最近动态

2023 年2 月，美国食品药物管理局批准Jesduvroq 片剂（daprodustat）作为第一种口服药物，用于治疗接受至少四个月透析的患者因慢性肾臟病引起的贫血（红血球计数低） 。Jesduvroq 未被批准用于透析患者以外的任何人。FDA 批准的其他治疗方法包括注射到血液中或透过皮肤给药。

调查的主要特征

  • 这份关于重组促红血球生成素市场的研究报告提供了以 2022 年为基准年的市场规模、复合年增长率 (CAGR %)、估计和预测 (2023-2030)。
  • 本研究报告让客户深入了解重组红血球生成素市场的最新发展。
  • 本研究报告阐明了各个区隔市场/国家的潜在成长机会，并解释了重组促红血球生成素市场有吸引力的投资主张矩阵。
  • 确定重组促红血球生成素市场的新投资机会、现有参与者面临的挑战以及永续成长因素
  • 研究范围详细讨论了重组促红血球生成素市场规模、预测、复合年增长率以及 COVID-19 对市场动态的影响。它还涵盖了对新冠疫情后重组促红血球生成素市场的详细见解。
  • 为了向本报告的用户提供重组促红血球生成素市场的全面了解，本报告也对重组促红血球生成素市场的竞争格局和主要创新者进行了分析。
  • 该研究涵盖了根据市场规模、成长率和吸引力对所有行业领域进行基准测试的成长前景映射分析。
  • 主要市场参与者的详细公司简介可协助您了解在重组促红血球生成素市场营运的公司的财务资讯和策略举措。
  • 此外，该报告还揭示了全球和区域市场主要参与者的重要收购和併购、联盟和合资企业、新产品发布、研发以及区域扩张。
  • 《全球重组促红血球生成素市场报告》面向该产业的各个利害关係人，主要是供应商、投资者、新进业者、经销商和财务分析师。

目录

第1章 基因重组促血红细胞生长素市场概要

  • 调查范围
  • 市场估计年数

第2章 摘要整理

  • 市场明细
  • 竞争考察

第3章 基因重组促血红细胞生长素的主要市场趋势

  • 基因重组促血红细胞生长素的市场促进因素
  • 基因重组促血红细胞生长素阻碍市场要素
  • 基因重组促血红细胞生长素的市场机会
  • 基因重组促血红细胞生长素市场未来趋势

第4章 基因重组促血红细胞生长素产业调查

  • PEST分析
  • 波特的五力分析
  • 成长预测的製图
  • 法规结构的分析

第5章 基因重组促血红细胞生长素市场:COVID-19感染疾病的影响分析

  • 新型冠状病毒感染疾病前的影响分析
  • 新型冠状病毒感染疾病后的影响分析

第6章 基因重组促血红细胞生长素的市场形势

  • 基因重组促血红细胞生长素市场占有率分析，2022年
  • 各主要製造商的明细资料
    • 确立的企业的分析
    • 新兴企业的分析

第7章 基因重组促血红细胞生长素市场- 各类型

  • 概要
    • 各类型市场区隔占有率分析
    • 红血球生成素Alpha
    • Darbe Poetin Alpha

第8章 基因重组促血红细胞生长素市场- 各适应症

  • 概要
    • 各适应症各市场区隔占有率分析
    • 慢性肾臟病(CKD)伴随的贫血
    • 癌症相关的贫血
    • HIV相关贫血
    • 其他

第9章 基因重组促血红细胞生长素市场- 各最终用途

  • 概要
    • 各最终用途市场区隔占有率分析
    • 医院和诊疗所
    • 透析中心
    • 肿瘤中心
    • 其他

第10章 基因重组促血红细胞生长素市场-各地区

  • 简介
  • 北美
    • 概要
    • 北美的基因重组促血红细胞生长素的主要製造商
    • 美国
    • 加拿大
  • 欧洲
    • 概要
    • 欧洲的基因重组促血红细胞生长素的主要製造商
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 其他
  • 亚太地区(APAC)
    • 概要
    • 亚太地区的基因重组促血红细胞生长素的主要製造商
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 其他
  • 南美
    • 概要
    • 南美的基因重组促血红细胞生长素的主要製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 其他
  • 中东和非洲
    • 概要
    • 中东及非洲的基因重组促血红细胞生长素的主要製造商
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 其他

第11章 主要供应商分析- 基因重组促血红细胞生长素产业

  • 竞争仪表板
  • 企业简介
    • Amgen Inc.
    • Johnson &Johnson
    • LG Chem Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Celltrion Inc.
    • Pfizer Inc.
    • Roche Holding AG
    • Novartis AG
    • Biocon Limited
    • Sandoz International GmbH
    • Intas Pharmaceuticals Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • 3SBio Inc.
    • CJ CheilJedang Corporation
    • BioSidus SA

第12章 分析师的全方位展望

Product Code: ANV1533

REPORT HIGHLIGHT

Recombinant Erythropoietin Market size was valued at USD 6,851.28 Million in 2022, expanding at a CAGR of 2.1% from 2023 to 2030.

Recombinant erythropoietin (rEPO) is a genetically modified type of erythropoietin, a hormone generated normally in the kidneys that controls red blood cell synthesis. rEPO is created through biotechnology, often using mammalian cells. It possesses the same form and function as endogenous erythropoietin and is utilized for treating anemia-related illnesses including chronic kidney failure, cancer-related anemia, and anemia caused by certain medicinal therapies. rEPO increases oxygen-carrying capacity in the blood by promoting the synthesis of red blood cells, enhancing energy levels, and minimizing the requirement for blood transfusions in patients with anemia.

Recombinant Erythropoietin Market- Market Dynamics:

Rising frequency of chronic kidney disease (CKD) and the necessity for efficient anaemia therapy to propel market demand

The rising frequency of chronic kidney disease (CKD) and the necessity for efficient anemia therapy is driving demand for recombinant erythropoietin (rEPO). Anaemia is common in CKD patients due to decreased erythropoietin production. rEPO, also known as Epoetin Alfa, is used to increase red blood cell formation, easing anemia symptoms and minimizing the requirement for blood transfusions. As the worldwide prevalence of CKD climbs owing to reasons such as aging populations and lifestyle changes, the healthcare sector's need for rEPO as a vital therapeutic option for anemia treatment in CKD patients grows.

Recombinant Erythropoietin Market- Key Insights:

  • As per the analysis shared by our research analyst, the global Recombinant Erythropoietin market is estimated to grow annually at a CAGR of around 2.1% over the forecast period (2023-2030)
  • The Recombinant Erythropoietin industry is projected to grow at a significant rate due to the rising frequency of chronic kidney disease (CKD) and the necessity for efficient anaemia therapy
  • Based on Type segmentation, Epoetin Alfa was predicted to show maximum market share in the year 2022
  • Based on Indication segmentation, Cancer Related Anemia was the leading type in 2022
  • On the basis of region, Asia Pacific was the leading revenue generator in 2022

Recombinant Erythropoietin Market- Segmentation Analysis:

The Global Recombinant Erythropoietin Market is segmented on the basis of Type, Indication, End-Use, and Region.

The market is divided into two categories based on Type: Epoetin Alfa, Darbepoetin Alfa. Epoetin Alfa, a kind of recombinant erythropoietin (rEPO), is in high demand since it is frequently used to treat anemia caused by chronic kidney disease, cancer chemotherapy, and other medical diseases. Epoetin Alfa promotes red blood cell synthesis, which helps to reduce anemia symptoms and enhance patients' quality of life.

The market is divided into four categories based on Indication: Anemia Associated with Chronic Kidney Disease (CKD), Cancer Related Anemia, HIV-Associated Anemia, Others. The Cancer Related Anemia sector dominates the market and is likely to maintain its dominance during the forecast period. In the treatment of cancer-related anemia, recombinant erythropoietin (rEPO) is in great demand. Patients taking chemotherapy for cancer often have a reduction in red blood cell formation, resulting in anemia. rEPO, especially Epoetin Alfa, is used to increase red blood cell synthesis, lowering the need for blood transfusions and increasing the general well-being of cancer patients.

Recombinant Erythropoietin Market- Geographical Insights:

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. Several reasons contribute to the high demand for recombinant erythropoietin (rEPO) in the Asia Pacific area. A considerable patient population in the area suffers from anemia-related illnesses such as chronic renal disease and cancer. Furthermore, the region's rapidly aging population and rising frequency of chronic illnesses boost demand for rEPO as a treatment option for anemia management. Furthermore, improving healthcare infrastructure as well as medical technology improvements led to the increased usage of rEPO in the Asia Pacific market. As a consequence, pharmaceutical firms are increasing their presence in the area to address the increasing demand for rEPO and other biologics.

Recombinant Erythropoietin Market- Competitive Landscape:

Because of its critical function in treating anemia-related disorders, recombinant erythropoietin (rEPO) faces severe competition. Several pharmaceutical firms are involved in the development and marketing of rEPO, creating a competitive environment. The market is dominated by key firms with well-established brands and substantial distribution networks. Companies strive for a competitive advantage by emphasizing product efficacy, safety, and cost-effectiveness. Furthermore, continuous R&D activities seek to enhance formulations and administration modalities, boosting patient comfort and compliance. The competitive dynamics are further influenced by strict regulatory compliance and patent protection.

Recent Developments:

In February 2023, The Food and Drug Administration authorised Jesduvroq tablets (daprodustat) as the first oral medication for anaemia (low red blood cell count) caused by chronic renal disease in individuals who have been receiving on dialysis for at least a four-month period. Jesduvroq is not authorised for non-dialysis patients. Other FDA-approved therapies for this illness are administered through injection into the bloodstream or via the skin.

Key features of the study:

  • This proposed research study on Recombinant Erythropoietin market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
  • The report provides the client the latest up-to-date and trending insights about the Recombinant Erythropoietin market.
  • The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Recombinant Erythropoietin market
  • The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Recombinant Erythropoietin market
  • Impact of COVID-19 on Recombinant Erythropoietin market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Recombinant Erythropoietin market post-COVID will also be covered.
  • In order to give the users of this report a comprehensive view on the Recombinant Erythropoietin market, we have also included competitive landscape and key innovator analysis for the Recombinant Erythropoietin market.
  • The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
  • The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Recombinant Erythropoietin market.
  • In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
  • The global Recombinant Erythropoietin market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET KEY PLAYERS

  • Amgen Inc.
  • Johnson & Johnson
  • LG Chem Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Celltrion Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Novartis AG
  • Biocon Limited
  • Sandoz International GmbH
  • Intas Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • 3SBio Inc.
  • CJ CheilJedang Corporation
  • BioSidus SA

GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET, BY TYPE

  • Epoetin Alfa
  • Darbepoetin Alfa

GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET, BY INDICATION

  • Anemia Associated with Chronic Kidney Disease (CKD)
  • Cancer Related Anemia
  • HIV-Associated Anemia
  • Others

GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET, BY END-USE

  • Hospitals and Clinics
  • Dialysis Centers
  • Oncology Centers
  • Others

GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Recombinant Erythropoietin Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Recombinant Erythropoietin Market Snippet by Type
    • 2.1.2. Recombinant Erythropoietin Market Snippet by Indication
    • 2.1.3. Recombinant Erythropoietin Market Snippet by End-Use
    • 2.1.4. Recombinant Erythropoietin Market Snippet by Country
    • 2.1.5. Recombinant Erythropoietin Market Snippet by Region
  • 2.2. Competitive Insights

3. Recombinant Erythropoietin Key Market Trends

  • 3.1. Recombinant Erythropoietin Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Recombinant Erythropoietin Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Recombinant Erythropoietin Market Opportunities
  • 3.4. Recombinant Erythropoietin Market Future Trends

4. Recombinant Erythropoietin Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Recombinant Erythropoietin Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Recombinant Erythropoietin Market Landscape

  • 6.1. Recombinant Erythropoietin Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Recombinant Erythropoietin Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2022 & 2030 (%)
    • 7.1.2. Epoetin Alfa
    • 7.1.3. Darbepoetin Alfa

8. Recombinant Erythropoietin Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2022 & 2030 (%)
    • 8.1.2. Anemia Associated with Chronic Kidney Disease (CKD)
    • 8.1.3. CancerRelated Anemia
    • 8.1.4. HIV-Associated Anemia
    • 8.1.5. Others

9. Recombinant Erythropoietin Market - By End-Use

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-Use, 2022 & 2030 (%)
    • 9.1.2. Hospitals and Clinics
    • 9.1.3. Dialysis Centers
    • 9.1.4. Oncology Centers
    • 9.1.5. Others

10. Recombinant Erythropoietin Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Recombinant Erythropoietin Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Recombinant Erythropoietin Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Recombinant Erythropoietin Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Recombinant Erythropoietin Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Recombinant Erythropoietin Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Recombinant Erythropoietin Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Amgen Inc.
    • 11.2.2. Johnson & Johnson
    • 11.2.3. LG Chem Ltd.
    • 11.2.4. Dr. Reddy's Laboratories Ltd.
    • 11.2.5. Celltrion Inc.
    • 11.2.6. Pfizer Inc.
    • 11.2.7. Roche Holding AG
    • 11.2.8. Novartis AG
    • 11.2.9. Biocon Limited
    • 11.2.10. Sandoz International GmbH
    • 11.2.11. Intas Pharmaceuticals Ltd.
    • 11.2.12. Teva Pharmaceutical Industries Ltd.
    • 11.2.13. 3SBio Inc.
    • 11.2.14. CJ CheilJedang Corporation
    • 11.2.15. BioSidus SA

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Recombinant Erythropoietin Market: Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Type
  • TABLE Global Recombinant Erythropoietin Market, by Type 2018-2030 (USD Million)
  • TABLE Recombinant Erythropoietin Market: Indication Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Indication
  • TABLE Global Recombinant Erythropoietin Market, by Indication 2018-2030 (USD Million)
  • TABLE Recombinant Erythropoietin Market: End-Use Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by End-Use
  • TABLE Global Recombinant Erythropoietin Market, by End-Use 2018-2030 (USD Million)
  • TABLE Recombinant Erythropoietin Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Recombinant Erythropoietin Market, by Region 2018-2030 (USD Million)
  • TABLE North America Recombinant Erythropoietin Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Recombinant Erythropoietin Market, by Type, 2018-2030 (USD Million)
  • TABLE North America Recombinant Erythropoietin Market, by Indication, 2018-2030 (USD Million)
  • TABLE North America Recombinant Erythropoietin Market, by End-Use, 2018-2030 (USD Million)
  • TABLE Europe Recombinant Erythropoietin Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Recombinant Erythropoietin Market, by Type, 2018-2030 (USD Million)
  • TABLE Europe Recombinant Erythropoietin Market, by Indication, 2018-2030 (USD Million)
  • TABLE Europe Recombinant Erythropoietin Market, by End-Use, 2018-2030 (USD Million)
  • TABLE Asia Pacific Recombinant Erythropoietin Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Recombinant Erythropoietin Market, by Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Recombinant Erythropoietin Market, by Indication, 2018-2030 (USD Million)
  • TABLE Asia Pacific Recombinant Erythropoietin Market, by End-Use, 2018-2030 (USD Million)
  • TABLE Latin America Recombinant Erythropoietin Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Recombinant Erythropoietin Market, by Type, 2018-2030 (USD Million)
  • TABLE Latin America Recombinant Erythropoietin Market, by Indication, 2018-2030 (USD Million)
  • TABLE Latin America Recombinant Erythropoietin Market, by End-Use, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Recombinant Erythropoietin Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Recombinant Erythropoietin Market, by Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Recombinant Erythropoietin Market, by Indication, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Recombinant Erythropoietin Market, by End-Use, 2018-2030 (USD Million)